Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.

The present invention relates to: a therapeutic composition for coronavirus comprising, as an active ingredient, one peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 6, and SEQ ID NO: 8 that binds to a coronavirus N-protein, a coronavirus-derived spike protein, or a fragment of the spike protein; and a composition that binds to a coronavirus N-protein comprising, as an active ingredient, the coronavirus-derived spike protein or the fragment of the spike protein. It is suggested that the peptides of the present invention, based on the understanding and targeting of the interaction of the coronavirus S protein and N protein of the present invention, have an effect that can be helpful in the treatment of coronaviruses including MERS-CoV, SARS-CoV-2, SARS-CoV, and HCoV-OC43.

This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of Adenovirus 36 E4orf1 protein or functional variant thereof.

The present invention provides methods for producing HIV-1 nanoparticle vaccines with enhanced immunogenicity. The methods entail (1) enzymatic digestion of glycan chain on the surface of a self-assembling nanoparticle vaccine displaying an HIV-1 Env derived trimer immunogen, or (2) expression of an HIV-1 nanoparticle construct in an expression system lacking normal glycosylation function for human proteins. Also provided in the invention are HIV-1 nanoparticle vaccines produced with the described methods. The invention further provides methods of using the HIV-1 nanoparticle vaccine compositions described herein in various therapeutic applications, e.g., for preventing or treating viral infections.

The disclosure features LNP compositions and systems comprising a therapeutic payload or prophylactic payload, a binding element, a tether molecule and/or an effector molecule and uses thereof. The LNP compositions or systems of the present disclosure comprise: (a) a first polynucleotide (e.g., mRNA) comprising: (1) a sequence encoding a therapeutic payload or prophylactic payload, and (2) a binding element; and (b) a second polynucleotide (e.g., mRNA) comprising a sequence encoding: (1) an effector molecule, and/or (2) a polypeptide that recognizes the binding element (a tether molecule). Such compositions or systems can: increase the level and/or activity of the therapeutic payload or prophylactic payload, e.g., increase the level, stability and/or activity of the mRNA encoding the therapeutic payload or prophylactic payload. Also disclosed herein are methods of treating a disorder, or for modulating an immune response in a subject using the disclosed LNP compositions or systems.

The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.

The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.

Aspects of the disclosure relate to isolated nucleic acids, rAAVs, and compositions configured to express an oxidative stress resistance protein (e.g., OXR1, NCOA7-AS, NCOA7-FL). In some embodiments, the compositions of the disclosure are useful for treatment of diseases or conditions associated with oxidative stress, for example neuronal degeneration.

The invention relates to the field of andeno-associated virus (AAV) based gene therapy, in particular to the use of a combination of recombinant AAV-transgene vectors with an immunosuppressant and/or empty-AAV capsids. The invention further provides a composition and a kit of parts based on this combination.